Head and Neck Neoplasms Clinical Trial
Official title:
A Phase II Study of Second-line Chemotherapy Combined With Endostatin for Recurrent/Metastatic Head and Neck Epithelial Tumors That Cannot be Re-irradiated or Re-operated After Fist-line Platinum-based Chemotherapy
The prognoses of recurrent/metastatic head and neck epithelial tumors after first-line platinum-based chemotherapy is poor. The efficacy of second-line chemotherapy for those patients that cannot be re-irradiated or re-operated is limited according to NCCN guideline and other published data. This study was designed to evaluate the efficacy and safety of endostatin combined with second-line chemotherapy for patients of recurrent/metastatic head and neck epithelial tumors that cannot be re-irradiated or re-operated after fist-line platinum-based chemotherapy.
The prognoses of recurrent/metastatic head and neck epithelial tumors after first-line platinum-based chemotherapy is poor. The efficacy of second-line chemotherapy for those patients that cannot be re-irradiated or re-operated is limited according to NCCN guideline and other published data. New agent for second-line treatment of recurrent and/or metastatic head and neck tumors is urgently needed. Recombinant human endostatin is an anti-angiogenetic target drug, which has been demonstrated a good efficacy for NSCLC. Studies about recombinant human endostatin in head and neck cancer mainly focus on NPC. And phase I study of endostatin combined with chemotherapy and/or radiotherapy for NPC showed a promising results. This study was designed to evaluate the efficacy and safety of endostatin combined with second-line chemotherapy for patients of recurrent/metastatic head and neck epithelial tumors that cannot be re-irradiated or re-operated after fist-line platinum-based chemotherapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05980598 -
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02548377 -
Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial
|
N/A | |
| Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06347185 -
Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study
|
N/A | |
| Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
| Terminated |
NCT02975739 -
Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors
|
N/A | |
| Recruiting |
NCT00982436 -
Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01025518 -
DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT00248235 -
Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00135161 -
Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer
|
Phase 1 | |
| Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
| Not yet recruiting |
NCT06458517 -
Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers
|
N/A | |
| Completed |
NCT05269342 -
Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer
|
N/A | |
| Recruiting |
NCT05544136 -
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
|
Phase 2 | |
| Terminated |
NCT03286972 -
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
|
||
| Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Recruiting |
NCT03678649 -
A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
|
Phase 2 | |
| Recruiting |
NCT03975465 -
EMST and Swallowing in Long-Term Survivors of HNCA
|
N/A | |
| Completed |
NCT03292250 -
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
|
Phase 2 | |
| Completed |
NCT06446570 -
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
|
Phase 2 |